Triple threat: radiation, chemo, and immunotherapy before surgery shows promise for oral cancer
NCT ID NCT07402538
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 3 trial tests whether giving a short course of targeted radiation (SBRT) followed by chemotherapy and immunotherapy before surgery can improve outcomes for people with advanced oral or HPV-negative throat cancer. About 184 participants will be randomly assigned to receive either this new combination or standard treatment. The main goal is to see if the combination increases the chance of being cancer-free two years after treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Stereotactic body radiotherapy (SBRT) plus tislelizumab, docetaxel, and cisplatin
What this could lead to
If successful, this approach could improve long-term survival and reduce recurrence for patients with advanced oral and throat cancers.
What could go wrong
This is an early-stage Phase 3 trial not yet recruiting. The combination of radiation, chemo, and immunotherapy may cause significant side effects, and results may not apply to all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OROPHARYNGEAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, 510060, China
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••